

Additional candidates to conventional genes susceptible for lung cancer and changing trend in Japan (Review)

ISAO OKAZAKI¹, MINORU SUGITA², HIDEAKI MATSUKI³,
SYED MUHAMMAD BAQUI BILLAH⁴ and TETSU WATANABE⁴

¹Department of Internal Medicine, Sanno Hospital, International University of Health and Welfare, 8-10-16 Akasaka, Minato-ku, Tokyo 107-0052; ²Department of Environmental and Occupational Health, Toho University School of Medicine, 5-21-16 Ohmorinishi, Ohta-ku, Tokyo 143-8540; Departments of ³Public Health, and ⁴Community Health, Tokai University School of Medicine, 134 Shimokasuya, Isehara City, Kanagawa 259-1193, Japan

Received January 7, 2010; Accepted March 2, 2010

DOI: 10.3892/or_00000788

Abstract. The polymorphism of *CYP1A1*2A* or *CYP1A1*2B*, and the linkage of *CYP1A1*2A*, *CYP1A1*2B*, *GSTM1* and *GSTT1* polymorphisms have been established as susceptible genes or gene-gene interactions of tobacco-related lung cancer. New candidate genes susceptible for lung cancer such as *NQO1* (NAD(P)H:quinine oxidoreductase), *NAT2* (N-acetyltransferase 2), and several others have been reported. In the present review we focus on new candidate genes susceptible for lung cancer, then examine all Japanese references by meta-analysis on susceptible genes over the past 20 years, and discuss whether new candidates and changing trend in Japan could be caused by environmental change.

Contents

1. Introduction
2. Conventional susceptible genes of tobacco-related lung cancer
3. New candidates of susceptible genes
4. Changing trend of susceptible genes in Japan
5. The possibility of genotype expression modified by environmental change
6. Future problems from the aspect of preventive medicine

Correspondence to: Dr Isao Okazaki, Department of Internal Medicine, Sanno Hospital, International University of Health and Welfare, 8-10-16 Akasaka, Minato-ku, Tokyo 107-0052, Japan
E-mail: iokazaki@iuhw.ac.jp

Abbreviations: CYP, cytochrome P-450; ETS, environmental tobacco smoke; GST, glutathione S-transferase; MPO, myeloperoxidase; NAT2, N-acetyltransferase 2; NQO1, NAD(P)H:quinine oxidoreductase; OR, odds ratio; SULT, sulfotransferase

Key words: lung cancer, susceptible genes, gene polymorphism, smoking, meta-analysis

1. Introduction

Cytochrome P-450 (CYP) enzymes have been reported to participate in chemical carcinogenesis and to form reactive intermediates which can then covalently bind to DNA. Formed DNA adducts show strong carcinogenic properties (1-3). This process is called phase I chemical reaction for carcinogenesis, whereas in phase II reaction DNA adducts are detoxified by glutathione S-transferase (GST) or other enzymes (1,3-5). Polymorphism of these CYPs shows different activities of aryl hydrocarbon hydroxylase to form DNA adducts (DNA-binding diol epoxide) (1-5). Benzo(a)pyrene, one of the carcinogenic agents in cigarettes, as well as other carcinogens are metabolized by CYP1A1, CYP1A2, CYP2A6, CYP2E1 and CYP2D6 to form benzo(a)pyrene DNA adducts (epoxide), resulting in very active carcinogens (1-5). The polymorphism of CYP1A1 have been shown at three sites, the MspI recognition site in intron (*CYP1A1*2A: MspI*), the isoleucine-to-valine substitution site in the heme-binding region of the enzyme (*CYP1A1*2B: Ile/Val*) and the threonine-to-asparagine substitution site in exon 7 of the enzyme (*CYP1A1*4*) (4-7). The distribution of gene polymorphism in both *CYP1A1*2A* and *CYP1A1*2B* was not the same between Japanese and Caucasian populations (6-9). Since the study of Kawajiri *et al* (10), the Japanese population showed a type of *CYP1A1* gene polymorphism significantly susceptible to tobacco-related lung cancer (11-16). On the other hand, Caucasians did not show significant distribution of either type of gene polymorphism of *CYP1A1* for non-small cell lung cancer (8,9,17). This ethnic difference may be considered due to the fact that the allelic frequency of *CYP1A1*2A(m2/m2)* and *CYP1A1*2B (Val/Val)* among Caucasians was about 10-fold less than among Japanese (7,8). Recent reports, however, based on pooled analysis of individual data of lung cancer cases and controls from the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogenesis revealed significantly higher cancer patients with *CYP1A1*2A* variant gene than controls (6,7,18,19). Next, the associated variant genes of *CYP1A1*2A*, *CYP1A1*2B*, *GSTM1* and *GSTT1* showed the high risk (13,19,20), and the gene-gene interactions of

*CYP1A1*2A*, *CYP1A1*2B*, *GSTM1* and *GSTT1* were clearly demonstrated to pose significantly high risk in the non-smoking persons of a large pooled studies by the detailed polymorphism analysis of their genes (7,21). Moreover *NQO1*, *NAT2* and several other genes have been reported as new susceptible genes of lung cancer (22-36). The present review focuses on new candidates, then examines all Japanese references by meta-analysis on susceptible genes over the past 20 years, and finally discusses whether new candidates and changing trend in Japan could be caused by environmental change.

2. Conventional susceptible genes of tobacco-related lung cancer

Kawajiri *et al* (10) were the first to demonstrate a strong association of the *CYP1A1*2A* genotype with the risk of lung cancer. In particular, in patients with squamous cell carcinoma the frequency of *CYP1A1*2A* (*m2/m2*) was 30.4%, while in healthy controls it was 10.6%. Subsequent studies (#2,4-7 in Table I) confirmed their study (10). Hayashi *et al* (#3 in Table I) also demonstrated an association of the *CYP1A1*2B* (*Val/Val*) with the risk of lung cancer, especially strong association in squamous cell carcinoma. This association was confirmed in three subsequent studies (#4,6,7 in Table I).

The significant association of these genes had not been reported in Caucasians people before the recent pooled analysis reports (7,8,18,19). There was an ethnic difference in the frequency of *CYP1A1* gene polymorphism in lung cancer, and the reason was considered due to the fact that the homozygous rare allele (*CYP1A1*2A* or *CYP1A1*2B*) in Caucasians occurs approximately ten times less frequently than in Japanese (6-9). However, recent studies based on pooled analysis of individual data of lung cancer cases and controls from the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogenesis revealed significant data of the higher frequency of *CYP1A1*2A* rare genotype in lung cancer compared with that in controls (7,8,18,19). The recent studies on lung cancer in Asian peoples naturally supported the significant data of the Kawajiri *et al* originals (37-39). The polymorphism of *CYP1A1* has been considered to involve in the phase I chemical reaction for carcinogenesis related with tobacco-related lung cancer.

The next conventional susceptible gene group is glutathione S-transferase that can detoxify formed DNA adducts in phase II reaction as mentioned above (1,3-5). Five classes of soluble glutathione-S-transferase (GSTs), alpha (A), mu (M), pi (P), theta (T) and zeta (Z), have been reported (5,40). *GSTM1* is involved in degradation of active metabolites of polycyclic aromatic hydrocarbons (41), and *GSTT1* in detoxification of small hydrocarbons such as monohalometanes and ethylene oxide in tobacco smoke (42). Null-type polymorphisms of *GSTM1* and *GSTT1* have been shown to cause deletion of glutathione S-transferase activity in the phase II chemical reaction which involves in tobacco-related lung cancer. It was reported not only in Caucasians (24,43,44) but also in Asian people (13,14,45,46), although *GSTT1* is still inconsistent (46,47).

Nakachi *et al* (13) found that the linkage of *CYP1A1* variants (*m2/m2* or *Val/Val*) and *GSTM1* null genotype showed a high susceptibility to lung cancer (nos. 3-5 in Table I). Since then positive reports were published (17,19-21,39). In a community-based study in Greece (47) the subjects carrying simultaneously three specific genotype combination of *CYP1A1*, *GSTM1* and *GSTT1* deviated from the common genotype in more than one gene, were over-represented in lung cancer patients. Hung *et al* (19) demonstrated the odds ratio (OR) of the combination of *CYP1A1*2B* variant gene and *GSTM1* null genotype was 4.67 (95% CI 2.00-10.9) compared with the concurrent presence of the *CYP1A1* wild-type and *GSTM1* non-null genotype in a pooled analysis of 14 case-control studies on lung cancer in Caucasian non-smokers. Recently Vineis *et al* (7) showed definite evidence of the gene-gene interactions of the polymorphisms of *CYP1A1*, *GSTM1* and *GSTT1* in a large pooled analysis of reported studies. Their significant data were observed in the non-smokers with OR of 3.71 (1.70-8.07), 3.99 (0.49-32.20), 4.51 (0.72-28.35) and 16.19 (1.90-137.65) for the combination of *GSTM1-GSTT1* double deletions with *CYP1A1*1*, *CYP1A1*2A*, *CYP1A1*2B* and *CYP1A1*4*, respectively ($P=0.13$) (reference *CYP1A1*1* and no deletion) (7). Non-smokers represent a population at the low level of exposure to carcinogens such as environmental tobacco smoke (ETS) and they were often overlooked because of the small number of cases (19). The association with smoking was notably higher for squamous cell carcinomas than for adenocarcinoma (7,18). Aforementioned Greek study showed strong positive association in heavy smokers (47). Thus, the gene-environment interactions in cases with these specific genotype combination have been reported.

3. New candidates of susceptible genes

The phase I chemical metabolites by CYP1A2, CYP2E1, and other CYPs may be involved in the increase in adenocarcinoma with the decrease in squamous cell carcinoma in lung cancer (23). CYP1A2 can catalyze the N-oxidation of several amines including heterocyclic amines in tobacco smoke or consuming well cooked meat or fish (5,23), and A/A genotype of *CYP1A2*1F* and G/G genotype of *CYP1A2*1C* increase the CYP1A2 activity with the association of lung adenocarcinoma (23).

CYP2E1 *Rsa1/Pst1* polymorphism was shown to be a decreased risk factor for the developing lung cancer among Asians (48). On the other hand, *CYP2E1* *c1/c1* genotype was associated with a significant increased risk for lung cancer in smokers with alcohol drinking (49). The induction of CYP2E1 is influenced by alcohol metabolism and this effect participates in the metabolic activation of various carcinogens such as N-nitrosodimethylamine (5,50). High consumption of alcohol beverage was known to be associated with increased lung cancer risk, whereas modest consumption was inversely associated with risk (51-53). *CYP2E1*1D* might involve in the development of alcohol and nicotine dependence (54).

N-acetyltransferases 2 (*NAT2*) and Sulfotransferase (*SULT*) *1A1* are included in phase II chemical reaction. *NAT2* participates in the detoxification of aromatic amines and is



No.	Author(s) (year)	Subjects	Summary	Refs.
1	Kawajiri <i>et al</i> , (1990)	68 lung cancer/104 healthy controls 23 squamous cell carcinoma/104 healthy controls	<i>CYP1A1</i> *2A (OR 3.09) (23.5%/10.6% <i>m2/m2</i>) <i>CYP1A1</i> *2A (OR 4.64) (30.4%/10.6% <i>m2/m2</i>)	10
2	Nakachi <i>et al</i> , (1991)	91 lung cancer/375 healthy controls (matched ^a 45/135) 60 adenocarcinoma/375 healthy controls	<i>CYP1A1</i> *2A (26.4%/10.6% <i>m2/m2</i> , <i>p</i> <0.001) (OR 7.31 lower-dose smokers, 1.13 *higher-dose smokers) <i>CYP1A1</i> *2A (13.3%/10.6% <i>m2/m2</i> , not significant)	11
3	Hayashi <i>et al</i> , (1992)	212 lung cancer/358 healthy controls 67 squamous cell carcinoma/ 358 healthy controls 96 adenocarcinoma/358 healthy controls	<i>CYP1A1</i> *2B and <i>GSTM1</i> null (OR 5.83; 12.3%/4.7% <i>Val/Val</i>) <i>CYP1A1</i> *2B and <i>GSTM1</i> null (OR 9.07; 14.9%/4.7% <i>Val/Val</i>)	12
4	Nakachi <i>et al</i> , (1993)	85 squamous cell carcinoma/matched ^a 170 healthy controls	<i>CYP1A1</i> *2A and <i>GSTM1</i> null (OR 16.0 lower-dose smokers; 20.0 higher-dose smokers) <i>CYP1A1</i> *2B and <i>GSTM1</i> null lower-dose smokers; 27.3 heavy)	13
5	Kihara <i>et al</i> , (1995)	97 male lung cancer (61 squamous and 36 small cell)/185 male smoker controls	<i>CYP1A1</i> *2A and <i>GSTM1</i> null (OR 8.3 at 0<SI<800; OR 21.9 at SI>800)	14
6	Nakachi <i>et al</i> , (1995)	125 adenocarcinoma (71 males, 54 females; 55 current, 25 ex-, 45 never smoked)/matched ^a 160 healthy controls	<i>CYP1A1</i> *2A (current or ex-; OR 3.25) <i>CYP1A1</i> *2B (poorly differentiated; OR 4.09) <i>CYP1A1</i> *2A (current or ex-; OR 3.22) <i>CYP1A1</i> *2B (poorly differentiated; OR 3.22)	15
7	Kiyohara <i>et al</i> , (1998)	108 lung cancer (56 adenocarcinoma, 30 squamous, 6 large cell, 16 small cell)/ 95 healthy male controls	<i>CYP1A1</i> *2A (OR 2.93) <i>CYP1A1</i> *2B (OR 3.45) AHH inducibility 7.0<(OR 12.4)	16
8	Sunaga <i>et al</i> , (2002)	198 lung adenocarcinoma (124 males 74 females)/152 hospital controls (108 males, 44 females) Non-smokers 75 (37.9%)/49 (32.2%) Smokers 65 (32.8%)/47 (30.9%)	<i>NQO1</i> (OR 2.15), <i>GSTT1</i> null (OR 1.61), linkage of both genes (OR 4.61) and more evident in smokers than non-smokers <i>CYP1A1</i> *2B (not significant), <i>GSTM1</i> (not significant), <i>OGG1</i> (not significant)	22
9	Kiyohara <i>et al</i> , (2003)	158 lung cancer female patients (140 adenocarcinoma, 10 squamous)/ matched 259 hospital non-smoking women	<i>CYP1A1</i> *2A (not significant) <i>GSTM1</i> null (OR 1.37), <i>GSTM1</i> null and high-dose ETS* (OR2.27)	57
10	Osawa <i>et al</i> , (2007)	113 lung cancer (68 adenocarcinoma 35 squamous; 74 males, 37 females)/ matched 121 healthy controls (73 males, 48 females), never smoked 32/55; light 21/18; heavy 58/43; unknown 2/5	<i>NAT2</i> (light smokers; OR 10.9) <i>NAT2</i> and <i>CYP1A2</i> *1F A/A (never smoked; OR 4.95) <i>CYP1A1</i> *2A/*2B (not significant), <i>CYP1A1</i> and <i>GSTM1</i> (not significant)	23

OR, odds ratio; SI, smoking index; ETS, environmental tobacco smoke; NAT2, N-acetyltransferase 2; NQO1, NAD(P)H:quinone oxidoreductase; OGG1, a DNA glycosylase for 8-hydroxyguanine. ^asex and age-matched case control study.

involved in N-acetylation (deactivation) and O-acetylation (activation) of a variety of polycyclic aromatic hydrocarbons (23). The slow genotype (23) and the fast genotype (25) among the polymorphisms of *NAT2* were shown to be related

with risk of lung cancer. Vineis *et al* (24) reported that *NAT2* slow genotype showed a higher odds ratio, though not significant, in subjects exposed to ETS in European Prospective Investigation into Cancer and Nutrition. *SULT 1A1* has been

known to participate in the detoxification of hydroxylated metabolites of polycyclic aromatic hydrocarbons and aromatic amines, and the variant allele of *SULT 1A1* was reported to be a risk factor for lung cancer in smokers (26).

Besides the phase I and phase II genes mentioned above, new candidate genes involved in oxidative stress have been investigated in the carcinogenesis of lung cancer (24). *NQO1* is a flavoenzyme in xenobiotic metabolism and protects cells from oxidative damage (24). *NQO1* -*Pro/Pro* and *Pro/Ser* genotypes have been reported as a significant susceptible gene for lung cancer in Mexican-Americans and African-Americans (27) and Taiwanese (28), although the specific histologic subtypes of lung cancer were not assessed. Subsequently the *NQO1*-*Pro/Pro* genotype has a higher enzymatic activity and was associated with the risk of lung adenocarcinoma (22,29). The 690C>T SNPs of *NQO1* has been associated with lower enzyme activity against protection and was significantly associated with lung cancer among never smokers (55) and in pooled analysis study of European Prospective Investigation into Cancer and Nutrition (24).

Myeloperoxidase (MPO) is a lysosomal enzyme in neutrophils and activates procarcinogens in tobacco smoke. The variant A allele is related with low metabolic activation and subsequently with low risk of lung cancer (30). The combination of *CYP1A1**2B rare genotype and *MPO* G/G genotype showed significantly increased risk of lung adenocarcinoma (31), although Vineis *et al* did not show *MPO* genotypes as the susceptible gene for lung cancer in a nested case-control study for non-smokers (24). At present time this candidate is still controversial.

Base excision repair (BER) genes, such as *OGG1* Ser326Cys, *XRCC1* Arg194Try, *XRCC1* Arg280His and *XRCC1* Arg399Gln, are considered to modulate DNA repair capacity and to be associated with the decrease or increase in risk of lung cancer (32,33). Among them the association between the *OGG1* Cys/Cys genotype and adenocarcinoma risk and between *XRCC1* Arg194Trp polymorphism and lung cancer risk among heavy smokers were observed (33).

Other recent studies (34-36) have revealed a strong and reliable association between genetic variation on chromosome 15 and risk of lung cancer. The association region contains several genes which encode nicotinic acetylcholine receptor subunits (*CHRNA5*, *CHRNA3*, and *CHRNA4*) although the presence of nicotine dependence was not consistent in three studies (34-36,56). That is, Thorgeirsson *et al* (35) pointed out that the variant has an effect on the number of cigarettes smoked per day in smokers and was significantly associated with nicotine dependence.

4. Changing trend of susceptible genes in Japan

Recent Japanese reports by Sunaga *et al* (#8 in Table I) and Osawa *et al* (23) neither showed any significant rare allele distribution of *CYP1A1* nor any significant linkage between *CYP1A1* and *GSTM1* for both smokers and those who had never smoked, but they did demonstrate novel types of gene polymorphism such as *NQO1* (8), *NAT2* for light smokers and linkage between *NAT2* and *CYP1A2**1F A/A for those who had never smoked (10). The majority of cases in the three recent studies surveyed in Japan (8-10) were adeno-

carcinoma. The incidence of adenocarcinoma increased in the 1990s in Japan similarly to other developed countries (58-61). Four studies (nos. 2, 3, 6 and 7) published before 1998 had examined the frequency of *CYP1A1**2A and *CYP1A1**2B rare variants in cases with adenocarcinoma. Although one of four studies (no. 2) showed almost the same distribution of the *CYP1A1**2A rare allele in healthy controls, the three other studies (nos. 3, 6 and 7) demonstrated a significant difference in the frequency of *CYP1A1**2A and/or *CYP1A1**2B rare variants of cases with lung adenocarcinoma compared with the controls. Among the references published after 2002, Kiyohara *et al* (57) investigated the association of ETS in non-smoking women with the occurrence of lung cancer and revealed a weak odds ratio for the *CYP1A1**2A and *GSTM1* variants. Therefore, a different frequency of *CYP1A1**2A and *CYP1A1**2B variants in patients with adenocarcinoma was noted in the studies published before 1998, but not noted in the reports published after 2002.

Then we examined whether the polymorphisms of genes had changed among the ten studies listed in Table I, that is, whether gene(s) susceptible to lung cancer had changed over the past 20 years. Seven studies published before 2000 (#1-7 in Table I) were compared with the three recent references published after 2001 (#8-10). The odds ratios of the rare alleles of *CYP1A1**2A, *CYP1A1**2B, and *GSTM1* null type susceptible genes reported in the references (Table I) were investigated by the meta-analysis method described previously (62).

Summarized odds ratios and their 95% confidence intervals (CI) of *CYP1A1**2A (*m2/m2*) vs. *CYP1A1**2A (*m1/m1*) susceptible to all lung cancer among the studies are shown in the upper half of Table II. Summarized odds ratios 'before 2000' were 2.493, i.e., greater than 1. This means that the incidence of lung cancer for the population of *CYP1A1**2A (*m2/m2*) was much greater than that of *CYP1A1**2A (*m1/m1*). The odds ratios (with 95% CI) of all references (eight studies) were 1.945 (1.258-3.006), and their p-value of homogeneity test was 0.009, in other words the odds ratios in the eight references were not homogeneous, but distributed diffusely (62,63). A comparison of summarized odds ratios between 'before 2000' and 'after 2001' groups showed large differences with significant p-value as well as homogeneity (62-64).

The lower half of Table II shows different results for *CYP1A1**2B (*Val/Val*) vs. *CYP1A1**2B (*Ile/Ile*). Summarized odds ratios 'before 2000' were larger than those 'after 2001' with respective homogeneity p-values, but there were no significant differences in the two groups.

The meta-analysis on genotype of *GSTM1* null to positive for all lung cancer showed that summarized odds ratios were 1.415 (1.104-1.813) 'before 2000' (three studies) and 1.287 (0.989-1.675) 'after 2001' (three studies) with no statistical differences, with respective homogeneity p-values.

Next, meta-analysis was conducted focusing on squamous cell carcinoma and adenocarcinoma separately. However, sufficient data were not available to compare the summarized odds ratios before 2000 and after 2001. Linkage of genotypes of *CYP1A1**2A, *CYP1A1**2B and *GSTM1* null type could not be obtained. AS *NQO1* and *NAT 2* appeared as candidate genes after 2001, we could not examine new candidate.



SPANDIDOS PUBLICATIONS summarized odds ratios and their 95% confidence intervals of genotypes of *CYP1A1**2A, and *CYP1A1**2B susceptible to all lung cancer studies listed in Table I, and p-value of statistical test between two groups, one before 2000 and one after 2001.

	Before 2000	After 2001	All refs.
<i>CYP1A1*2A (m2/m2) vs. CYP1A1*2A (m1/m1)</i>			
Summarized odds ratios	2.493 (1.677-3.705)	0.899 (0.537-1.506)	1.945 (1.258-3.006)
No. of studies	6	2	8
No. of references in Table I	(1,2,4-7)	(9,10)	(1,2,4-7,9,10)
P-value of homogeneity test	0.151	0.807	0.009
P-value of test for the two groups	0.00259		
<i>CYP1A1*2B (Val/Val) vs. CYP1A1*2B (Ile/Ile)</i>			
Summarized odds ratios	2.199 (1.074-4.502)	1.278 (0.551-2.964)	1.887 (1.105-3.221)
No. of studies	4	2	6
No. of references in Table I	(3,5-7)	(8,10)	(3,5-8,10)
P-value of homogeneity test	0.176	0.521	0.220
P-value of test for the two groups	0.391		

Methods of meta-analysis: when the odds ratio and its 95% CI were given in an article, they were employed for the present meta-analysis. If the odds ratio and its 95% CI are not reported in an article but could be calculated from the contents of the article by the method described previously (62), the values calculated were used for the present meta-analysis. If the odds ratio and its 95% CI were not given in an article and the values could not be calculated from the contents of the article by any means, the article was removed from the present meta-analysis study. Summarized odds ratios and their 95% CIs were calculated by the method of Fleiss and Gross (63) as described previously (62). When odds ratios for meta-analysis were homogeneous, a fixed-effect model was used (62,63), and in other cases the random-effects model by DerSimonian and Laird (64) was used as described previously (62). The original method for *CYP1A1**2A polymorphism is based on RFLPs of the *CYP1A1* gene digested with *MspI* (10,65), but most of the cases in the first study of Kawajiri *et al* (10) were examined by the PCR-RFLP method developed by Kawajiri *et al* (66). Since then the PCR-RFLP method by Kawajiri *et al* (10) has been used in all references. *CYP1A1**2B polymorphism analysis based on PCR by Hayashi *et al* (12) was used in all references. GSTM1 positive or null genotype based on the PCR method by Comstock *et al* (67) and Groppi *et al* (68) was used by Hayashi *et al* (12) and Nakachi *et al* (13). Other references (14,23,57) used the same PCR method, although two references cited other studies (69,70). Therefore, these genotypes were in principal examined by the same PCR so the references could be compared for the meta-analysis.

The results of our meta-analysis study mentioned above suggest that *CYP1A1**2A (*m2/m2*) is not a susceptible gene for lung cancer at present time, and susceptible genes for lung cancer might have changed during 2 decades. Our meta-analysis study, however, has not sufficient evidence because the numbers of studies after 2000 were few, the study sizes in Table I were not large, and the study designs were different. The controls used in two studies (nos. 1 and 3) were 104 and 358 healthy individuals over 40 years old with no information regarding sex or smoking. Controls matched for sex and age were reported in five studies (#2,4,6,8 and 10, Table I). Although cigarette doses were not matched, analysis was performed on cigarette doses in these five studies. Recent report of Asian pooled analysis (48) was not investigated chronologically and included all cases and controls in 11 Asian countries, different life styles and different environment. We should investigate the environment-modified polymorphism expression of susceptible genes for lung cancer in a large pooled analysis.

5. The possibility of genotype expression modified by environmental change

Environmental change such as air pollution, indoor pollution, the chemical contents of cigarettes, food and other substances might affect the transcription of *CYP1A1**2A followed by

increased protein levels of *CYP1A1* related with AHH activity, more than that of *CYP1A1**2B, over the past few decades in Japan if the conventional susceptible genes have changed in patients with lung cancer. The reports of NQO1 and NAT2 may suggest the involvement of oxidative stress *in vivo* in the occurrence of lung cancer. The metabolites of *CYP1A2*, *CYP2E1*, and other CYPs may be involved in the increase in adenocarcinoma with the decrease in squamous cell carcinoma in lung cancer (5,23). *CYP1A2* involves the metabolism of N-oxidation of several amines such as the heterocyclic amines formed when meat and fish are cooked well. The amines are also formed in tobacco smoke (1-5). The effect of heavy or moderate alcohol drinking with/without smoking may cause a complicated condition on *CYP2E1* activity induced by alcohol drinking, and *CYP2E1* is also involved in the metabolic activation of various N-nitrosamines including the potent tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (71).

In Japan habitual male smokers decreased from 53.1% in 1990 to 39.4% in 2007, while females increased from 9.7 to 11.0% (72). Environmental changes also took place over the past two decades in Japan. As for lifestyle, housing, food, clothes, cosmetics, perfumes, and drugs have not changed much except for increased consumption of meat and instant or conserved food. Increased meat consumption may cause induction of NAT2 (22), and may also be consistent

with the remarkable recent increase in the incidence of breast cancer as well as colon cancer in Japan (72). Another noticeable change is less pollution of air, water, sand and roads. Strict monitoring for dioxin is also conducted for industrial air and water. Recent trends in Japan including less pollution and increased meat consumption may have changed the CYP1A1 gene polymorphism susceptible to tobacco-related lung cancer.

The increase in incidence of adenocarcinoma has been considered to be related to the increased consumption of filtered cigarettes, which contain low tar and nicotine but increased nitrate (0.5-1.3%) (30,73). In Japan low-tar under 15 mg and low-nicotine under 1 mg cigarettes accounted for over a 50% share of consumption in 1983, while low-tar under 11 mg and low-nicotine under 1 mg cigarettes accounted for over 50% after 1991 (74).

The occurrence of adenocarcinoma in the lung may involve the oxidative stress *in vivo* with injury to the alveolar cells, which result in the uncontrolled proliferation of lung alveolar cancer stem cells (75,76). In this process many chemical reactants including tobacco-smoke, other chemical particles stimulate macrophages and neutrophils to produce proteinases such as matrix metalloproteinases, elastase and others as well as cytokines which destroy alveolar cells. If the inflammation or damage to alveolar cells continues, bronchoalveolar stem cells may transform to cancer cells (75,76). Tobacco smoke is one of the most important carcinogens, but we do not think tobacco-smoke is alone responsible for lung cancer. We should follow new susceptible candidate genes in patients with lung cancer in order to prevent the most prevailed lung cancer.

6. Future problems from the aspect of preventive medicine

Excellent studies based on pooled analysis of individual data of lung cancer cases and controls from the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogenesis (6,7,19,21,24) did not show the chronological change of susceptible genes. We should clarify the possibility of new candidate susceptible genes from the aspects of preventive medicine. For this reason we propose the need for a prospective study in the selected cities in the world for the genes susceptible to lung cancer related with environmental change from the chronological aspect.

The change of our life-styles may add new susceptible gene candidates to lung cancer beyond the conventional susceptible genes. We should investigate whether the possibility of environment-modified genotype expression occurs in future.

Acknowledgements

This study was supported in part by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (IO, 13557034). The authors thank Ms. Yoshie Muroya for the systematic literature search.

References

- Boddy AB and Ratain MJ: Pharmacogenetics in cancer etiology and chemotherapy. *Clin Cancer Res* 3: 1025-1030, 1997.
- Kiyohara C, Hirohata T and Inutsuka S: The relation between aryl hydroxylase and polymorphisms of the CYP1A1 gene. *Jpn J Cancer Res* 87: 18-24, 1996.
- Hecht SS: Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. *Lancet Oncol* 3: 461-469, 2002.
- Brockmoeller J, Cascorbi I, Kerb R, Sachse C and Roots I: Polymorphisms in xenobiotic conjugation and disease predisposition. *Toxicol Lett* 102-3: 173-183, 1998.
- Oyama T, Matsumoto A, Isse T, Kim YD, Ozaki S, Osaki T, Sugio K, Yasumoto K and Kawamoto T: Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. *Anticancer Res* 23: 1731-1738, 2003.
- Vineis P, Veglia F, Benhamou S, *et al.*: CYP1A1 T³⁸⁰¹ C polymorphism and lung cancer: a pooled analysis of 2,451 cases and 3,358 controls. *Int J Cancer* 104: 650-657, 2003.
- Vineis P, Anttila S, Benhamou S, *et al.*: Evidence of gene-gene interactions in lung carcinogenesis in a large pooled analysis. *Carcinogenesis* 28: 1902-1905, 2007.
- Houlston RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. *Pharmacogenetics* 10: 105-114, 2000.
- Hivronen A, Husgafvel-Pursiainen A, Karjalainen S, Anttila S and Vainio H: Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. *Cancer Epidemiol Biomarkers Prev* 1: 485-459, 1992.
- Kawajiri K, Nakachi K, Imai K, Yoshii A, Shinoda N and Watanabe J: Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. *FEBS* 263: 131-133, 1990.
- Nakachi K, Imai K, Hayashi S, Watanabe J and Kawajiri K: Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. *Cancer Res* 51: 5177-5180, 1991.
- Hayashi S, Watanabe J and Kawajiri K: High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and Mu-class glutathione S-transferase genes. *Jpn J Cancer Res* 83: 866-870, 1992.
- Nakachi K, Imai K, Hayashi S and Kawajiri K: Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. *Cancer Res* 53: 2994-2999, 1993.
- Kihara M, Kihara M and Noda K: Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. *Carcinogenesis* 16: 2331-2336, 1995.
- Nakachi K, Hayashi S, Kawajiri K and Imai K: Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. *Carcinogenesis* 16: 2209-2213, 1995.
- Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S and Hirohata T: The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. *Pharmacogenetics* 8: 315-323, 1998.
- Alexandrie A-K, Nyberg F, Warholm M and Rannug A: Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. *Cancer Epidemiol Biomarkers Prev* 13: 908-914, 2004.
- Le Marchand L, Guo C, Benhamou S, *et al.*: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). *Cancer Causes Control* 14: 339-346, 2003.
- Hung RJ, Boffetta P, Brockmoller J, *et al.*: CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. *Carcinogenesis* 24: 875-882, 2003.
- Belogubova EV, Ulibina YM, Suvorova, *et al.*: Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects. *J Cancer Res Clin Oncol* 132: 327-331, 2006.
- Vineis P, Veglia F, Anttila S, *et al.*: CYP1A1, GSTM1 and GSTT1 polymorphisms and lung cancer: a pooled analysis of gene-gene interactions. *Biomarkers* 9: 298-305, 2004.
- Sunaga N, Kohno T, Yanagitani N, *et al.*: Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. *Cancer Epidemiol Biomarkers Prev* 11: 730-738, 2002.



- SPANDIDOS^Y, Osawa K, Miyaishi A, *et al*: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. *Asian Pac J Cancer Prev* 8: 103-108, 2007.
24. Vineis P, Veglia F, Garte S, *et al*: Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in non-smokers. *Ann Oncol* 18: 1230-1242, 2007.
 25. Chiou HL, Wu MF, Chien WP, Cheng YW, Wong RH, Chen CY, Lin TS and Lee H: NAT2 fast genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. *Cancer Lett* 223: 93-101, 2005.
 26. Wang Y, Spitz MR, Tsou AM, Zhang K, Maken N and Wu X: Sulfotransferase (SULT) 1A1 polymorphism as a predisposition factor for lung cancer: a case-control analysis. *Lung Cancer* 35: 137-142, 2002.
 27. Wiencke JK, Spitz MR, McMillan A and Kelsey KT: Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H:quinine oxidoreductase polymorphism. *Cancer Epidemiol Biomark Prev* 6: 87-92, 1997.
 28. Chen H, Lum A, Seifried A, Wilkens LR and LeMarchand L: Association of the NAD(P)H:quinine oxidoreductase 609C->T polymorphism with a decreased lung cancer risk. *Cancer Res* 59: 3045-3048, 1999.
 29. Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ and Chen CY: NAD(P)H:quinine oxidoreductase polymorphism and lung cancer in Taiwan. *J Toxicol Environ Health A* 58: 187-197, 1999.
 30. Kiyohara C, Yoshimasu K, Takayama K and Nakanishi Y: NQO1, MPO, and the risk of lung cancer: a HuGE review. *Genet Med* 7: 463-478, 2005.
 31. Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV and Fong KM: CYP1A1 Ile462Val and MPO G-463A interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. *Carcinogenesis* 27: 525-532, 2006.
 32. Hung RJ, Hall J, Brennan P and Boffetta P: Genetic polymorphisms in the Base Excision repair pathway and cancer risk: a HuGE review. *Am J Epidemiol* 162: 925-942, 2005.
 33. Hung RJ, Brennan P, Canzian F, *et al*: Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. *J Natl Cancer Inst* 97: 567-576, 2005.
 34. Hung RJ, McKay JD, Gaborieau V, *et al*: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature* 452: 633-637, 2008.
 35. Thorgeirsson TE, Geller F, Sulem P, *et al*: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* 452: 638-642, 2008.
 36. Amos CI, Wu X, Broderick P, *et al*: Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nature Genet* 40: 616-622, 2008.
 37. Lin P, Wang SL, Wang HJ, Chen KW, Lee HS, Tsai KJ, Chen CY and Lee H: Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma. *Brit J Cancer* 82: 852-857, 2000.
 38. Song N, Tan W, Xing D and Lin D: CYP1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. *Carcinogenesis* 22: 11-16, 2001.
 39. Ng DPK, Tan K-W, Zhao B and Seow A: CYP1A1 polymorphisms and risk of lung cancer in non-smoking Chinese women: incidence of environmental tobacco smoke exposure and GSTM1/T1 genetic variation. *Cancer Causes Control* 16: 399-405, 2005.
 40. Mannervik B, Awasthi YC, Board PG, *et al*: Nomenclature for human glutathione transferases. *Biochem J* 282: 305-308, 1992.
 41. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP and Kadlubar FF: The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. *Environ Health Perspect* 98: 87-94, 1992.
 42. Guengerich FP, Thier R, Persmark M, Taylor JB, Pemble SE and Ketterer B: Conjugation of carcinogens by theta class glutathione S-transferases: mechanisms and relevance to variations in human risk. *Pharmacogenetics* 5 (Suppl): 103-107, 1995.
 43. Houlston RS: Glutathione S-transferase M1 status and lung cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 8: 675-682, 1999.
 44. Benhamou S, Lee WJ, Alexandrie AK, *et al*: Meta- and pooled analysis of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. *Carcinogenesis* 23: 1343-1350, 2002.
 45. Raimondi S, Paracchini V, Autrup H, *et al*: Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. *Am J Epidemiol* 164: 1027-1042, 2006.
 46. Lee KM, Kang D, Clapper NL, *et al*: CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. *Cancer Epidemiol Biomarkers Prev* 17: 1120-1126, 2008.
 47. Dialyna I, Miyakis S, Georgatou N and Spandidos DA: Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. *Oncol Rep* 10: 1829-1835, 2003.
 48. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, Wei SZ, Yu LK and Song Y: CYP2E1 Rsa1/Pst1 polymorphism is associated with lung cancer risk among Asians. *Lung Cancer* (In press).
 49. Eom SY, Zhang YW, Kim SH, Choe KH, Lee KY, Park JD, Hong YC, Kim YD, Kang JW and Kim H: Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. *Cancer Causes Control* 20: 137-145, 2009.
 50. Hong J, Pan J, Dong Z, Ning SM and Yang CS: Regulation of N-nitrosodimethylamine demethylase in rat liver and kidney. *Cancer Res* 47: 5948-5953, 1987.
 51. Chao C: Associations between beer, wine, and liquor consumption and lung cancer risk: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 16: 2436-2447, 2007.
 52. Chao C, Slezak JM, Caan BJ and Quinn VP: Alcoholic beverage intake and risk of lung cancer: the California Men's Health Study. *Cancer Epidemiol Biomarkers Prev* 17: 2692-2699, 2008.
 53. Shimazu T, Inoue M, Sasazuki S, Iwasaki M, Kurahashi N, Yamaji T and Tsugane S: Alcohol and risk of lung cancer among Japanese men: data from a large-scale population-based cohort study, the JPHC study. *Cancer Causes Control* 19: 1095-1102, 2008.
 54. Howard LA, Ahluwalia JS, Lin SK, Sellers EM and Tyndale RF: CYP2E1*1D regulatory polymorphism: association with alcoholism and nicotine dependence. *Pharmacogenetics* 13: 321-328, 2003.
 55. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR and Schwartz AG: CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. *Carcinogenesis* 26: 2207-2212, 2005.
 56. Chanock SJ and Hunter D: Genomics When the smoke clears... *Nature* 452: 537-538, 2008.
 57. Kiyohara C, Wakai K, Mikami H, Sido K, Ando M and Ohno Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: a case-control study in Japanese non-smoking women. *Int J Cancer* 107: 139-144, 2003.
 58. Sobue T, Ajiki W, Tsukuma H, Oshima A, Hanai A and Fujimoto I: Trends of lung cancer incidence by histologic type: a population-based study in Osaka, Japan. *Jpn J Cancer Res* 90: 6-15, 1999.
 59. Toyoda Y, Nakayama T, Ioka A and Tsukuma H: Trends in lung cancer incidence by histological type in Japan. *Jpn J Clin Oncol* 38: 534-539, 2008.
 60. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD and Heath CW Jr: Cigarette smoking and changes in the histopathology of lung cancer. *J Natl Cancer Inst* 89: 1580-1586, 1997.
 61. Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histological type: male:female differences diminishing and adenocarcinoma rising. *Int J Cancer* 117: 294-299, 2005.
 62. Sugita M, Izuno T, Tatemichi M and Otawara Y: Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. *J Epidemiol* 11: 87-94, 2001.
 63. Fleiss JL and Gross AJ: Meta-analysis in epidemiology, with special reference to study of the association between exposure to environmental tobacco smoke and lung cancer: a critique. *J Clin Epidemiol* 44: 127-188, 1991.
 64. DerSimonian R and Laird N: Meta-analysis in clinical trials. *Contr Clin Trials* 7: 177-188, 1986.
 65. Gonzalez FJ, Jaiswal AK and Nebert DW: Cold Spring Harbor Sym. *Quant Biol* L1: 879-890, 1986.
 66. Kawajiri K, Watanabe J, Gotoh O, Tagashira Y, Sogawa K and Fujii-Kuriyama Y: Structure and drug inducibility of the human cytochrome P-450c gene. *Eur J Biochem* 159: 219-225, 1986.
 67. Comstock KE, Sanderson JS, Claflin G and Henner WD: GST1 gene deletion determined by polymerase chain reaction. *Nucleic Acids Res* 18: 3670, 1990.

68. Groppi A, Coutelle C, Fleury B, Iron A, Begueret J and Couzigou P: Glutathione S-transferase class mu in French alcoholic cirrhotic patients. *Human Genet* 87: 628-630, 1991.
69. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, Wolf CR and Spurr NK: Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. *Carcinogenesis* 12: 1533-1537, 1991.
70. Arand M, Muhlbauer R, Hengstler J, Jaeger E, Fuchs J, Winkler L and Oesch F: A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. *Anal Biochem* 236: 184-186, 1996.
71. Yang CS, Yoo JS, Ishizaki H and Hong JY: Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanism of regulation. *Drug Metab Rev* 22: 147-159, 1990.
72. Ministry of Health, Labor and Welfare, Japan, 2007.
73. B'chir F, Laouani A, Ksibi S, Arnaud MJ and Saguem S: Cigarette filter and the incidence of lung adenocarcinoma among Tunisian population. *Lung Cancer* 57: 26-33, 2007.
74. The website of TIOJ< <http://www.tioj.or.jp/index.html>>
75. Houghton AM, Mouded M and Shapiro SD: Common origins of lung cancer and COPD. *Nature Med* 14: 1023-1024, 2008.
76. Adair-Kirk TL, Atkinson JJ and Senior RM: Smoke particulates stress lung cells. *Nature Med* 14: 1024-1025, 2008.